As per a recent market analysis by Future Market Insights (FMI), the global pharmaceutical lipids market size totaled US$ 4.44 Bn in 2021. With sales growing at a 5.1% CAGR, the market valuation is set to reach US$ 7.70 Bn by 2032.
Increasing demand for various drug formulations to treat chronic diseases across the globe is expected to drive sales of pharmaceutical lipids.
Stringent regulations pertaining to manufacturing and distribution of excipients, mandated by the International Pharmaceutical Excipient Council (IPEC) will improve the manufacturing of better quality ingredients for pharmaceutical drugs.
Furthermore, efforts by governments and regulatory agencies in developed nations, such as the U.S. and the U.K., to streamline the approval process for excipients, are expected to push sales in the market.
Oral solid dosage forms are the dominant mode of delivery in the pharmaceutical lipids market and are the preferred option for many pharmaceutical products due to their cost-effectiveness and patient compliance.
The use of capsules or tablets for a drug delivery offers benefits such as increased physical and chemical stability, convenience of handling, unique brand recognition by color and shape, and controlled-release options.
Most liposomal drugs are based on oral solid drug formulations. Ease of consumption among patients, especially children is expected to boost sales of oral drugs, which will have a direct impact on the sales of pharmaceutical lipids.
For example, around 50% of patients find it difficult to swallow conventional hard solid tablets. This has encouraged drug manufacturers to develop more innovative solid oral product forms, such as effervescent tablets, orally disintegrating granules (ODGs), lozenges, chewable tablets, and instant drinks. This is expected to create substantial demand for liposomal excipients during the forecast period, thereby augmenting the growth in the market.
“Increasing investments in contract manufacturing of pharmaceutical lipids, along with growing demand for oral solid drug formulation is expected to augment the growth in the market over the forecast period,” says an FMI analyst.
Get Sample PDF Brochure:
https://www.futuremarketinsights.com/reports/sample/rep-gb-10983
Key Takeaways:
- Based on product type, sales of triglycerides are expected to hold over 44.3% market by 2032 and are expected to increase at a 5.1% CAGR over the forecast period.
- By form, the semi-solid segment is leading with over 60.0% of market share in 2021 and is projected to account 62.7% of the total market share by 2032.
- In terms of source, sales in the semi-synthetic sources segment will grow at a 5.8% CAGR.
- Applications in the conventional lipid-based drug delivery systems (LBDDS) segment accounted for a dominant share of 64.4% in 2021.
- Oral pharmaceutical lipids will emerge as the most widely adopted route of administration. The segment held 40.8% of the total market share in 2021.
- The U.S. will continue dominating the North America pharmaceutical lipids market over the forecast period owing to the presence of a robust healthcare sector.
- Demand in the U.K. pharmaceutical lipids market will surge at a 5.1% CAGR over the assessment period.
- Sales in the India market are slated to increase at a 5.2% CAGR, accounting for a lion’s share in the South Asia pharmaceutical lipids market.
Competition Landscape
Acquisitions, mergers, expansion, development of an extensive clinical pipeline and product launches are the key strategies adopted by manufacturers to increase the consumer base in various countries. For instance:
- In July 2020, ABITEC announced the acquisition of Larodan AB, a manufacturer and international marketer of state-of-the-art, high-purity research grade lipids. The acquisition expanded ABITEC’s functional lipid product offerings and scientific capabilities to better serve the pharmaceutical, nutritional, and industrial markets.
- In January 2020, BASF completed the acquisition of polyamide business of Solvay.
- In July 2020, Croda International Plc announced the acquisition of Avanti Polar Lipids, Inc., a knowledge-intensive leader in lipid-based drug delivery technologies for the next generation of pharmaceuticals.
Ask for Customization:
https://www.futuremarketinsights.com/customization-available/rep-gb-10983
Key Market Segments Covered in Pharmaceutical Lipids Industry Research
By Product:
- Triglycerides
- Phospholipids
- Sphingolipids
- Cholesterol
- Fatty Acids
- Others
By Source:
- Synthetic
- Semi-synthetic
- Natural
By Form:
- Liquid
- Semi-solid
- Solid
By Application:
- Conventional Lipid-based Drug Delivery Systems
- Self-Emulsifying Drug Delivery Systems
- Self-Microemulsifying Drug Delivery Systems
- Liposomes
- Solid Lipid Nanoparticles
- Nanostructured Lipid Carriers
- Others
By Route of Administration:
- Oral
- Tablet
- Solution
- Parenteral
- Intravenous
- Intramuscular (Vaccines)
- Topical
By Region:
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- Middle East and Africa (MEA)
Inquire Before Buying This Research Report:
https://www.futuremarketinsights.com/ask-question/rep-gb-10983
About Us
Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.
Contact:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com